Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
D-Street Buzz: Bank, oil gas stocks rally led by Bank of Baroda, HPCL; RIL hits record high, Adani Power spikes 12%

2018-07-12 moneycontrol
The Indian benchmark indices are trading on a positive note this Thursday morning with the Nifty jumping 78 points and is trading above the 11,000 mark while the Sensex is trading higher by 257 points at 36,522, reaching a new record high.
500408 500325 533096 HCTHY 512599 532480 500696 532281 EROSMEDIA GODREJCP CHENNPETRO RLNIY SBAZ ANNRY AXB ALBK YYBKY 532424 AXBA HCLTECH 500180 KOTAKBANK ADANIENT RELIANCE HINDUNILVR 533155 JUBLFOOD 532215 GDRJY 532187 532461 AXISBANK RIGD JBLWY HDFCBANK 500110 YESBANK UBNC INDUSINDBK KMBKY 533261 IBN 532648 AXBKY ICICIBANK PNJZY HDB 532174 TATAELXSI PNB ADANIPOWER 500247

4
HPCL, BPCL, IOC fall 6-8% after Brent crude oil prices spike over $77/bbl

2018-06-27 moneycontrol
The share prices of oil marketing companies ended sharply lower on Wednesday after crude oil prices jumped over $77 a barrel.
IOC BPCL 500547 BRQPY HINDPETRO 530965 500104 500110 CHENNPETRO

3
CPCL gets nod for taking up Nagapattinam refinery expansion

2018-05-10 moneycontrol
Chennai Petroleum Corporation has been given in-principle approval for its Rs 27,000 crore refinery expansion project in Tamil Nadu, a top official said today.
IOC 530965 500110 CHENNPETRO

0
IOC to invest Rs 1.4 lakh crore to double refining capacity

2018-03-31 moneycontrol
India's biggest oil firm IOC today said it plans to invest about Rs 1.43 lakh crore to nearly double its oil refining capacity to 150 million tonnes and boost petrochemical production by 2030.
500110 CHENNPETRO

3
Indian Oil to invest Rs1.4 trillion to double refining capacity

2018-03-31 livemint
New Delhi: India’s biggest oil firm IOC on Saturday said it plans to invest about Rs1.43 trillion to nearly double its oil refining capacity to 150 million tonnes and boost petrochemical production by 2030.
IOC 530965 500110 CHENNPETRO

35
Market Update: PSU Bank index up 1% led by SBI; CNX IT drags as Wipro falls 2%; GAIL, HPCL shed up to 4%

2018-03-26 moneycontrol
The Indian equity market was trading almost flat on Monday morning with the Nifty trading lower by 9 points, trading below the 10,000 mark at 9988 while the Sensex was up 25 points or 0.08 percent.
IOC CAPF TCHQY 532755 CADILAHC 532321 BJJQY GAILF 500570 CHENNPETRO SBAZ PTC YYBKY 530965 TECHM BAJFINANCE TATASTEEL TATLY GAMMONIND GAILY 509550 TCS 523204 532938 IDBI 533155 TTNQY JUBLFOOD ABAN 500470 532540 532187 532461 JBLWY SKFINDIA TATAMOTORS 500472 500110 500034 YESBANK UBNC 500116 INDUSINDBK IBN 532648 532524 CDLYY ICICIBANK TTST PNJZY 532174 PNB TTM

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...